Physician profile
Devri N Cashe
NPI 1912303744
$8,185.40
in general payments reported to CMS, 2019-2025
25 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,905 · 2022: $1,672 · 2023: $1,987 · 2024: $1,529 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,534 · Education: $74.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,533.85 |
| Education | $74.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,973.48 | 2021-2025 | Dovato, Rukobia, Apretude |
| Astrazeneca Pharmaceuticals LP | $1,179.76 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Gilead Sciences, INC. | $1,011.47 | 2021-2025 | Biktarvy |
| Novo Nordisk INC | $499.04 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $452.37 | 2021-2025 | Pifeltro, Delstrigo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.99 | 2021-2024 | Jardiance |
| Amarin Pharma, INC. | $412.25 | 2021-2023 | |
| Lilly USA, LLC | $295.58 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $278.03 | 2021-2022 | |
| Theratechnologies INC. | $273.42 | 2021-2025 | Egrifta, Trogarzo |
| Bayer Healthcare Pharmaceuticals INC. | $241.36 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.52 | 2021-2023 | Xifaxan |
| Janssen Biotech, INC. | $173.42 | 2022-2023 | Prezcobix |
| Braeburn INC. | $136.57 | 2024-2025 | Brixadi |
| Biohaven Pharmaceutical Holding Company LTD. | $109.50 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $88.37 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $85.02 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $57.72 | 2021 | |
| Indivior INC. | $56.87 | 2021 | |
| Amgen INC. | $52.28 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $52.24 | 2021 | |
| Sunovion Pharmaceuticals INC. | $47.22 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.28 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $18.50 | 2024 | Quviviq |
| Abbott Laboratories | $17.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devri Cashe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.